Sign In
Buy BMRN
$56.47
+1.81 (+3.31%)
At Close: Jun 04, 2026
5 Biopharmas Where BofA Would Put Its Money To Work
11:23am, Friday, 08'th May 2020
Biopharma shares have outperformed the broader market year-to-date, giving rise to apprehension over whether a pullback is in the offing.
BioMarin: Appeal Is On The Increase
03:23pm, Monday, 04'th May 2020
BioMarin: Appeal Is On The Increase
BioMarin Strikes Gene Therapy Partnership Targeting Rare Genetic Cardiomyopathies
10:43am, Monday, 04'th May 2020
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is beefing up its gene therapy portfolio.
BioMarin (BMRN) Beats on Q1 Earnings, Lowers Sales View
09:47am, Thursday, 30'th Apr 2020
BioMarin (BMRN) beats estimates for both earnings and sales in the first quarter. It lowers its total revenue outlook for the year due to the potential impact of coronavirus outbreak.
BioMarin Blows Past Q1 Estimates, Projects 1st Year of Profitability in 2020
06:54am, Thursday, 30'th Apr 2020
The biotech is experiencing some disruption from the COVID-19 pandemic, but not enough to derail its growing momentum.
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean-Jacques Bienaimé on Q1 2020 Results - Earnings Call Transcript
01:06am, Thursday, 30'th Apr 2020
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean-Jacques Bienaimé on Q1 2020 Results - Earnings Call Transcript
BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings and Revenue Estimates
05:45pm, Wednesday, 29'th Apr 2020
BioMarin (BMRN) delivered earnings and revenue surprises of 90.91% and 6.73%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
CFRA Analysts Highlight 6 Health Sector Buys For Your Portfolio
01:31pm, Wednesday, 29'th Apr 2020
In spite of Covid-19 and global recession concerns, we have a positive outlook on the biotechnology sub-industry; we expect to see a ramp-up in new drug sales; the continued development of many new, i
Goldman Sachs Says Buy 4 Biotech Stocks in Front of Q1 Earnings
07:15am, Monday, 27'th Apr 2020
In what has become truly the most challenging investing environment in decades, it is probably no surprise to most investors that health care is the top-performing sector this year in the S&P 500.
Biomarin Could Possibly Be The First To Obtain FDA Approval For Hemophilia Gene Therapy Treatment
07:59am, Wednesday, 15'th Apr 2020
Biomarin Could Possibly Be The First To Obtain FDA Approval For Hemophilia Gene Therapy Treatment
Is BioMarin Pharmaceuticals Stock a Buy?
07:36am, Wednesday, 08'th Apr 2020
Is this a prime opportunity for investors to buy the gene therapy drugmaker?
Vertex Pharmaceuticals And BioMarin Pharmaceutical: 2 Safe Biotech Picks To Buy During This Bear Market
02:35pm, Tuesday, 07'th Apr 2020
Vertex Pharmaceuticals And BioMarin Pharmaceutical: 2 Safe Biotech Picks To Buy During This Bear Market
Biomarin to File Regulatory Applications for Vosoritide in Q3
11:04am, Tuesday, 07'th Apr 2020
BioMarin (BMRN) plans to file regulatory applications seeking approval for its achondroplasia candidate, vosoritide, in the third quarter of 2020.
BioMarin (BMRN) Down 8% Since Last Earnings Report: Can It Rebound?
11:30am, Friday, 27'th Mar 2020
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?
Why BioMarin Pharmaceutical, Bristol-Myers Squibb, and bluebird bio Are Getting Hammered Monday
01:41pm, Monday, 16'th Mar 2020
These biopharma stocks are taking a big hit because of the COVID-19 pandemic.
